GlassScriptPhysician profile
Michael V Antworth
NPI 1649254020
$2,644.22
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $447 · 2020: $412 · 2021: $745 · 2022: $1,023 · 2023: $16.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $2,121.33 | 2019-2022 | |
| Genentech USA, INC. | $141.85 | 2019-2023 | Vabysmo |
| Allergan, INC. | $98.24 | 2019-2021 | |
| Alimera Sciences, INC. | $70.42 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $69.21 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $56.12 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $55.76 | 2019-2020 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Eyepoint US, INC. | $11.89 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$78,085.07 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Antworth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.